Cocrystal Pharma, Inc.

Sam S Lee

Irina C Jacobson

Michael David Feese

Wang Shen

Xiaoling Zheng

Biing Yuan Lin

Michael D Feese

Provided herein are compounds of Formula A, B or C that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication

Disclosed herein are combination therapies for use in the treatment or prevention of HCV by administering Compound A and a second HCV inhibitor.

Combination therapy for treatment of HCV

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection. 

Inhibitors of hepatitis C virus polymerase

The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R, and Rare as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection. 

Growing community of inventors

Lynnwood, WA, United States of America

Sam S Lee